Results 181 to 190 of about 16,411 (192)

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

New England Journal of Medicine, 2018
Nick van Es, Peter Verhamme, Marc Carrier   +2 more
exaly  

Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban

New England Journal of Medicine, 2014
Sasha H Bakhru, Robert J Noveck
exaly  

Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial

Circulation, 2018
Robert P Giugliano, Elliott M Antman, Eugene Braunwald   +2 more
exaly  

Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes

New England Journal of Medicine, 2023
exaly  

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Circulation, 2017
Raffaele De Caterina, Jonathan Halperin, Giulia Renda   +2 more
exaly  

Edoxaban for Cancer-Associated Venous Thromboembolism

New England Journal of Medicine, 2018
Harry R Büller
exaly  

Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate

Circulation, 2015
Hamim Zahir, Elliott M Antman
exaly  

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British Journal of Clinical Pharmacology, 2016
Dolly A Parasrampuria
exaly  

Edoxaban in Asian Patients With Atrial Fibrillation

Journal of the American College of Cardiology, 2018
So-Ryoung Lee, Eue-Keun Choi, Kyung-Do Han   +2 more
exaly  

Edoxaban versus Warfarin for Venous Thromboembolism

New England Journal of Medicine, 2014
exaly